Browsing Barts Cancer Institute by Subject "Women's Health"
Now showing items 1-1 of 1
-
Phase 2 study to evaluate the novel mitochondrial PRX3 inhibitor, RSO-021, as an intrapleural monotherapy and in combination with IV paclitaxel in patients with malignant pleural effusion due to mesothelioma or another advanced solid tumor.
(American Society of Clinical Oncology (ASCO), 2024-05-29)